| Literature DB >> 30953562 |
Balasingam Nisahan1, Thirunavukarasu Kumanan2, Nadarajah Rajeshkannan3, Thampipillai Peranantharajah4, Mahalingam Aravinthan4.
Abstract
OBJECTIVE: Prevalence of erectile dysfunction (ED) in diabetic men is considerably high but it is often underdiagnosed and undermanaged. There were no data available about the prevalence and the risk factors of ED in our region. So a cross-sectional study was conducted to identify the prevalence and associated risk factors of ED in a tertiary care diabetic center in Northern Sri Lanka.Entities:
Keywords: Co existing hypertension; Diabetes; Erectile dysfunction
Mesh:
Substances:
Year: 2019 PMID: 30953562 PMCID: PMC6451292 DOI: 10.1186/s13104-019-4244-x
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Hypertensive medication usage among participants
Fig. 2Distribution of severity of erectile dysfunction among study participants
Association between selected factors with erectile dysfunction
| Characteristics (variables) | Status of erectile dysfunction | Level of significance and odds ratio with 95% CI | ||
|---|---|---|---|---|
| Presence | Absence | Total | ||
| Age above 40** | 187 (57.4%) | 87 (26.7%) | 274 (84.0%) | P < 0.0001, OR: 3.73 (CI 2.01–6.93) |
| Type of diabetes** | P-0.014, OR: 3.66 (CI 1.22–10.96) | |||
| Type 1 | 5 (1.5%) | 10 (3.1%) | 15 (4.6%) | |
| Type 2 | 201 (61.6%) | 110 (33.7%) | 311 (95.4%) | |
| Duration of diabetes** > 5 years | 111 (34.0%) | 31 (9.5%) | 142 (43.6%) | P < 0.0001, OR: 3.35 (CI 2.05–5.49) |
| Poor diabetic control (HbA1C ≥ 7) | 135 (41.4%) | 67 (20.6%) | 202 (62.0%) | P-0.082, OR: 1.50 (CI 0.95–2.38) |
| Unsafe level of alcohol consumption** | 82 (25.2%) | 26 (8.0%) | 108 (33.1%) | P-0.001, OR: 1.34 (CI 1.14–1.56) |
| Smoker | 50 (15.3%) | 21 (6.4%) | 71 (21.8%) | P-0.153, OR: 0.66 (CI 0.38–1.17) |
| With micro-vascular complications** | 105 (32.2%) | 44 (13.5%) | 149 (45.7%) | P-0.012, OR: 1.80 (CI 1.11–2.85) |
| With diabetic neuropathy** | 40 (12.3%) | 10 (3.1%) | 50 (15.3%) | P-0.007, OR: 1.33 (CI 1.12–1.57) |
| With diabetic nephropathy** | 64 (19.6%) | 19 (5.8%) | 83 (25.5%) | P-0.002, OR: 1.32 (CI 1.13–1.54) |
| With retinopathy | 49 (15.0%) | 23 (7.1%) | 72 (22.1%) | P-0.332, OR: 0.76 (CI 0.44–1.33) |
| With macro vascular complications | 23 (7.1%) | 7 (2.2%) | 30 (9.2%) | P-0.108, OR: 2.03 (CI 0.843–4.88) |
| Co-existing hypertension** | 113 (34.7%) | 39 (12.0%) | 152 (46.6%) | P < 0.0001, OR: 1.39 (CI 1.18–1.64) |
| Hyperlipidaemia | 95 (29.1%) | 50 (15.3%) | 145 (44.5%) | P < 0.436, OR: 1.07 (CI 0.91–1.26) |
| Taking beta-blockers** | 13 (4.0%) | 1 (0.3%) | 14 (4.3%) | P = 0.019, OR: 1.50 (CI 1.27–1.78) |
| BMI ≥ 25** | 94 (28.8%) | 39 (12.0%) | 133 (40.8%) | P = 0.035, OR: 1.74 (CI 1.09–2.79) |
**Significant factors